NRC FORM 591M PART 1
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Mosaic Life Care 902 N. Riverside Rd., St. Joseph, MO & 5325 Faraon St., St. Joseph, MO REPORT NUMBER(S) 2016-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14791	24-18287-01	6/1/16, with in-office review through 6/15/16

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

_____ Non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert G. Gattone, Jr.	Robert G. Gattone, Jr.	6/24/16
BRANCH CHIEF	Aaron T. McCraw		6/24/16

NRC FORM 591M PART 3
(07-2012)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Mosaic Life Care 902 N. Riverside Rd., St. Joseph, MO & 5325 Faraon St., St. Joseph, MO REPORT NUMBER(S) 2016-001	Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-14791	24-18287-01	6/1/16, with in-office review through 6/15/16

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87132 & 87131	For IP 87132 & IP 87131: 02.01 through 02.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02230	2	Chris Bowen, AMP	(402) 968-3842

☑ Main Office Inspection Next Inspection Date: 06/01/2018

☐ Field Office Inspection _____

☐ Temporary Job Site Inspection _____

PROGRAM SCOPE

The in-office review included receipt and review of new information that was unavailable during the onsite inspection. The licensee had not received any iridium-192 high dose rate HDR afterloader device sources yet. There was no licensed material at the N. Riverside Rd. facility during the onsite inspection. The authorized medical physicist (AMP) planned to call the NRC Region III office when the licensee receives its first iridium-192 source. The licensee conducted 35.300 activities at the Faraon St. facility including radium-223 Xofigo metastasis treatments and iodine-131 treatments for thyroid cancer and hyperthyroidism. The licensee also conducted 35.400 activities at the Faraon St. facility including cesium-137 for gynecological cancer treatments and iodine-125 for prostate cancer treatments. The licensee did not do positron emission tomography. The College St. facility: (1) had no licensed material since January 26, 2016; (2) was a restricted and secured area; and (3) was planned to be used again for licensed activities in a few months.

Performance Observations

The inspector: (1) used a calibrated NRC owned survey instrument to measure a maximum of 0.03 millroentgen per hour at selected surfaces of a sealed wooden box from Varian containing the licensee's HDR device at the licensee's N. Riverside Rd. facility; and a maximum of 0.4 milliroentgen per hour at selected surfaces in a hot lab; (2) observed that the HDR facility was as authorized; (3) observed a nuclear medicine technologist (NMT) use a dose calibrator to measure a capsule containing 15.3 millicuries of iodine-131 prior to administering it to a patient; (4) observed an NMT provide radiation safety instructions to the patient that received the iodine-131 capsule; (5) observed that a licensee's survey instrument was calibrated as required; (6) noted that proper technique was used to determine the dose calibrator potentiometer setting for radium-223; (7) reviewed several Xofigo and iodine-131written directives and applicable records showing that the administrations were in accordance with the written directives (e.g., dosage activity verification, radiopharmaceutical verification, and dual patient identification verification); (8) reviewed selected Radiation Safety Committee meeting minutes; (9) reviewed dosimeter badge records showing that whole body and extremity doses were well below regulatory limits; (10) reviewed selected records of area surveys; (11) reviewed selected program audit records; (12) observed an NMT prepare and administer a diagnostic imaging dosage; (13) reviewed selected iodine-125 prostate implant records which showed that the administrations were administered in accordance with the written directives and treatment plans; and (14) reviewed selected cesium-137 gynecological implant records which showed that the administrations were administered in accordance with the written directives and treatment plans.